Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to ...

The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia. The FDA has granted Fast ...

The Department of Health and Human Services, which oversees FDA and other health agencies, did not immediately respond to a ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

(RTTNews) - Sanofi (SNYNF, SNY) announced Wednesday that the US Food and Drug Administration has granted fast track designation to the company's mRNA vaccine candidate for the prevention of ...

Several pharma companies – Arcturus Therapeutics, Bayer, GSK, Moderna, Pfizer, and Sanofi - are all racing to develop mRNA influenza vaccines. GSK has teamed up with CureVac and currently has ...